Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: Possible roles of Akt/NF- κ B pathway

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Xu, Feng ^a   Wang, Yuehui ^a   Cui, Wenpeng ^a   Yuan, Hang ^a   Sun, Jing ^a   Wu, Man ^a   Guo, Qiaoyan ^a   Kong, Lili ^a   Wu, Hao ^a   Miao, Lining ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; RESVERATROL;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME REPRESSION; GLOMERULUS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CORTEX; KIDNEY MASS; MALE; MESANGIUM CELL; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS;

EID: 84897811327     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/289327     Document Type: Article

References (33)

1. Kanwar Y. S., Wada J., Sun L., Xie P., Wallner E. I., Chen S., Chugh S., Danesh F. R., Diabetic nephropathy: mechanisms of renal disease progression. Experimental Biology and Medicine 2008 233 1 4 11 2-s2.0-37549035027 10.3181/0705-MR-134
2. Young B. A., Johnson R. J., Alpers C. E., Eng E., Gordon K., Floege J., Couser W. G., Cellular events in the evolution of experimental diabetic nephropathy. Kidney International 1995 47 3 935 944 2-s2.0-0028931063
3. Chen L., Zhang J., Zhang Y., Wang Y., Wang B., Improvement of inflammatory responses associated with NF- B pathway in kidneys from diabetic rats. Inflammation Research 2008 57 5 199 204 2-s2.0-46449103466 10.1007/s00011-006-6190-z
4. Park C. W., Kim J. H., Lee J. W., Kim Y. S., Ahn H. J., Shin Y. S., Kim S. Y., Choi E. J., Chang Y. S., Bang B. K., High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF- κ B-dependent. Diabetologia 2000 43 12 1544 1553 2-s2.0-0034434874 10.1007/s001250051567 (Pubitemid 32734862)
5. Galkina E., Ley K., Leukocyte recruitment and vascular injury in diabetic nephropathy. Journal of the American Society of Nephrology 2006 17 2 368 377 2-s2.0-33645454310 10.1681/ASN.2005080859
6. Navarro J. F., Mora C., Role of inflammation in diabetic complications. Nephrology Dialysis Transplantation 2005 20 12 2601 2604 2-s2.0-27944493244 10.1093/ndt/gfi155 (Pubitemid 41672253)
7. de la Lastra C. A., Villegas I., Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Molecular Nutrition and Food Research 2005 49 5 405 430 2-s2.0-20344407841 10.1002/mnfr.200500022 (Pubitemid 40780389)
8. Kim M. Y., Lim J. H., Youn H. H., Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1 α axis in db/db mice. Diabetologia 2013 56 1 204 217
9. Zhang S., Cai G., Fu B., SIRT1 is required for the effects of rapamycin on high glucose-inducing mesangial cells senescence. Mechanisms of Ageing and Development 2012 133 6 387 400
10. Zhang L., Pang S., Deng B., Qian L., Chen J., Zou J., Zheng J., Yang L., Zhang C., Chen X., Liu Z., Le Y., High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF- B/NADPH oxidase/ROS pathway, which is inhibited by resveratrol. The International Journal of Biochemistry and Cell Biology 2012 44 4 629 638 2-s2.0-84857918130 10.1016/j.biocel.2012.01.001
11. Cui W., Li B., Bai Y., Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice. American Journal of Physiology Endocrinology and Metabolism 2013 304 1 87 99
12. Cui W., Bai Y., Miao X., Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation. Oxidative Medicine and Cellular Longevity 2012 2012 12 821936 10.1155/2012/821936
13. Ždychov J., Komers R., Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiological Research 2005 54 1 1 16 2-s2.0-14944381279 (Pubitemid 40363649)
14. Yang Y., Wang J., Qin L., Rapamycin prevents early steps of the development of diabetic nephropathy in rats. American Journal of Nephrology 2007 27 495 502 (Pubitemid 47482007)
15. Rane M. J., Song Y., Jin S., Barati M. T., Wu R., Kausar H., Tan Y., Wang Y., Zhou G., Klein J. B., Li X., Cai L., Interplay between Akt and p38 MAPK pathways in the regulation of renal tubular cell apoptosis associated with diabetic nephropathy. American Journal of Physiology 2010 298 1 F49 F61 2-s2.0-74049097246 10.1152/ajprenal.00032.2009
16. Sheu M. L., Ho F. M., Chao K. F., Kuo M. L., Liu S. H., Activation of phosphoinositide 3-kinase in response to high glucose leads to regulation of reactive oxygen species-related nuclear factor- B activation and cyclooxygenase-2 expression in mesangial cells. Molecular Pharmacology 2004 66 1 187 196 2-s2.0-3042530936 10.1124/mol.66.1.187 (Pubitemid 38822102)
17. Palsamy P., Subramanian S., Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochimica et Biophysica Acta 2011 1812 7 719 731 2-s2.0-79955634116 10.1016/j.bbadis.2011.03.008
18. Sharma S., Anjaneyulu M., Kulkarni S. K., Chopra K., Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006 76 2 69 75 2-s2.0-31144447091 10.1159/000089720 (Pubitemid 43131538)
19. Kitada M., Kume S., Imaizumi N., Koya D., Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1- independent pathway. Diabetes 2011 60 2 634 643 2-s2.0-79551601710 10.2337/db10-0386
20. Tikoo K., Singh K., Kabra D., Sharma V., Gaikwad A., Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radical Research 2008 42 4 397 404 2-s2.0-48849086013 10.1080/10715760801998646
21. Ding D., You N., Wu X., Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK. American Journal of Nephrology 2010 31 363 374
22. Jiang B., Guo L., Li B. Y., Resveratrol attenuates early diabetic nephropathy by down-regulating glutathione S-transferases Mu in diabetic rats. Journal of Medicinal Food 2013 16 481 486
23. Fröjdö S., Cozzone D., Vidal H., Pirola L., Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochemical Journal 2007 406 3 511 518 2-s2.0-34548730196 10.1042/BJ20070236 (Pubitemid 47425457)
24. Lee F. T. H., Cao Z., Long D. M., Panagiotopoulos S., Jerums G., Cooper M. E., Forbes J. M., Interactions between angiotensin II and NF- B-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. Journal of the American Society of Nephrology 2004 15 8 2139 2151 2-s2.0-3543069402 10.1097/01.ASN.0000135055.61833.A8 (Pubitemid 39031352)
25. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., Makino H., Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF- B activation. American Journal of Physiology 2007 292 4 F1141 F1150 2-s2.0-34147213227 10.1152/ajprenal.00288.2005 (Pubitemid 46578056)
26. Usui H., Shikata K., Matsuda M., HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrology Dialysis Transplantation 2003 18 2 265 272 (Pubitemid 36181675)
27. Fornoni A., Ijaz A., Tejada T., Lenz O., Role of inflammation in diabetic nephropathy. Current Diabetes Reviews 2008 4 1 10 17 2-s2.0-38949105531 10.2174/157339908783502361 (Pubitemid 351216880)
28. Guijarro C., Egido J., Transcription factor- B (NF- B) and renal disease. Kidney International 2001 59 2 415 424 2-s2.0-0035137324 10.1046/j.1523-1755. 2001.059002415.x (Pubitemid 32157906)
29. Lee H. B., Ha H., Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology 2005 10 2 11 13
30. Okada S., Shikata K., Matsuda M., Ogawa D., Usui H., Kido Y., Nagase R., Wada J., Shikata Y., Makino H., Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003 52 10 2586 2593 2-s2.0-0141866840 10.2337/diabetes.52.10.2586 (Pubitemid 37210549)
31. Chow F. Y., Nikolic-Paterson D. J., Ozols E., Atkins R. C., Tesch G. H., Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. Journal of the American Society of Nephrology 2005 16 6 1711 1722 2-s2.0-26944480830 10.1681/ASN.2004070612 (Pubitemid 41716477)
32. Beg A. A., Baltimore D., An essential role for NF- B in preventing TNF- α -induced cell death. Science 1996 274 5288 782 784 2-s2.0-0029976817 10.1126/science.274.5288.782 (Pubitemid 26398258)
33. Liu Z.-G., Hsu H., Goeddel D. V., Karin M., Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF- B activation prevents cell death. Cell 1996 87 3 565 576 2-s2.0-0030298294 10.1016/S0092-8674(00)81375-6 (Pubitemid 26374329)